Swiss Life Sciences Stock News

SWX:KNIN
SWX:KNINShipping

Kuehne + Nagel International (SWX:KNIN) Posts Mixed Results, Is The Premium Already Priced In?

Kuehne + Nagel International (SWX:KNIN) released mixed results for the second quarter and first half of 2026, giving investors fresh detail on how the logistics group is performing across different reporting periods. See our latest analysis for Kuehne + Nagel International. Over the past year Kuehne + Nagel International has combined a 12.59% 90 day share price return with a 28.07% 1 year total shareholder return, suggesting improving momentum even though the 3 and 5 year total shareholder...
SWX:SUN
SWX:SUNMachinery

Sulzer (SWX:SUN) Half Year Profit Strength Puts Its Valuation Back In Focus

Sulzer (SWX:SUN) drew fresh investor attention on 28 July 2026 after reporting half year 2026 results, with net income and earnings per share higher despite lower sales compared with the prior period. See our latest analysis for Sulzer. Against this earnings backdrop, Sulzer’s share price has moved to CHF146.40, with a 1 month share price return of 10.08% but a year to date share price return that is down 3.56%. The 3 year total shareholder return of 87.63% and 5 year total shareholder return...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis (SWX:NOVN) Gains A New Pluvicto Growth Case As Valuation Stays In Focus

Novartis (SWX:NOVN) is back in focus after the US Food and Drug Administration approved an expanded use of Pluvicto in combination with androgen receptor pathway inhibitors for PSMA-positive metastatic hormone-sensitive prostate cancer. See our latest analysis for Novartis. Novartis shares have been firming over 2026, with a 16.68% year to date share price return and a 38.50% total shareholder return over one year, as investors weigh the expanded Pluvicto approval alongside recent earnings,...
SWX:CLN
SWX:CLNChemicals

Clariant (SWX:CLN) Stock Faces Profit Fragility Despite Cost Saving Progress

Clariant came into this earnings print trading at CHF9.15 after a strong run over the past month, yet the latest half-year numbers still tell a turnaround story in progress rather than one already secured. The stock looks inexpensive on simple sales multiples, but the headline from H1 2026 is that profitability remains fragile. Group EBITDA before exceptionals held at a mid to high teens margin, while the company remained loss making over the last twelve months and net debt edged higher to...
SWX:INRN
SWX:INRNMachinery

Interroll Holding (SWX:INRN) Stock Faces Margin Squeeze Despite Solid Demand

Interroll Holding stock has been treading water in recent weeks, with a small gain of just over 3% in the past month and a double digit slide over the past quarter. The earnings headline that cuts through the noise is margin pressure. First half 2026 delivered a 10% EBIT margin and net profit of CHF 19.8m, slightly softer despite solid intralogistics demand. The market sees a high quality balance sheet, a trailing P/E of 20.2x and analyst forecasts that point to faster earnings growth than...
SWX:HOLN
SWX:HOLNBasic Materials

Holcim (SWX:HOLN) Stock Faces A Valuation Puzzle After Profit Reset

Holcim stock closed at CHF73.34 on the day of the results and has drifted slightly lower over the past week. The market reaction looks muted for a company that just reported mid single digit organic net sales growth and double digit organic recurring EBIT growth in the first half. The real story is not today’s small move in the share price. It is how investors weigh that earnings power against a P/E above 100x that is anchored in a year affected by a CHF1.3b one off loss. Is Holcim a genuine...
SWX:AVOL
SWX:AVOLSpecialty Retail

Avolta (SWX:AVOL) Stock Rich Valuation Meets Stronger Profit And Cash Flow

Avolta closed at CHF48.34 after the H1 2026 release, roughly flat over the past week and still down about 11% over the past month. The stock is trading on a rich P/E of 31.9x, yet the latest half shows the earnings story that has kept investors engaged. Net income reached CHF35.0m with basic earnings per share of CHF0.25, and management kept the focus on cash with equity free cash flow of €207m and leverage around 2.07x. The key issue for investors is whether that earnings and cash mix...
SWX:BANB
SWX:BANBLife Sciences

Bachem (SWX:BANB) Stock Faces Margin Strain As Capex Surges

Bachem Holding walked into this earnings season with a growth-stock label and a rich P/E of 37.6x, yet the share price has drifted down about 3% over the past month to CHF 74.80. Today's H1 numbers put the spotlight on something less glamorous and more important for you as an investor. The peptide and oligonucleotide specialist is pouring money into capacity, with H1 capital expenditure of CHF 148m and EBITDA margin sitting at 25.4%. The key question is whether this heavy build-out and margin...
SWX:IFCN
SWX:IFCNElectronic

INFICON Holding (SWX:IFCN) Can Profit Recovery Justify Its 50.2x P/E?

INFICON Holding stock closed at CHF162.60 on 31 July, roughly flat over the past week after a choppy few months. The market reaction looks cautious. The earnings story is not. H1 2026 showed clear profit recovery in a capital intensive semiconductor equipment world, with basic earnings per share at US$2.27 and trailing net profit margin at 13.5%. The immediate price move tells you how traders felt today. The multi year forecasts and the valuation you are paying for that recovery are what...
SWX:KARN
SWX:KARNMachinery

Kardex Holding (SWX:KARN) Profit Warning Tests Whether Its Valuation Still Holds

Why Kardex Holding Stock Is Back In Focus After Its Half Year 2026 Results Kardex Holding (SWX:KARN) is back on investor radars after its half year 2026 update, which combined strong growth in bookings and order backlog with a 40% EBIT decline and a profit warning. The company reported half year sales of €440.5 million compared with €415.7 million a year earlier, while net income moved from €36.2 million to €22.6 million and basic EPS from €4.69 to €2.93. See our latest analysis for Kardex...
SWX:IDIA
SWX:IDIABiotechs

Idorsia (SWX:IDIA) Stock Price Hinges On QUVIVIQ Growth And Funding Risk

Idorsia closed at CHF6.12, roughly flat over the past week but still carrying a strong 90 day rebound in the share price. The market has been treating this as a recovery story. The Q2 earnings headline pulls investors back to the balance sheet. The company is still loss making and carries negative shareholders’ equity, and yet trades on a price to sales ratio of 7.8x, below both the European biotech average and key peers. The central question now is whether the liquidity moves and earnings...
SWX:ZEHN
SWX:ZEHNBuilding

Zehnder Group (SWX:ZEHN) Profit Recovery Raises Fresh Questions Over Margin Durability

Zehnder Group stock closed at CHF67.70 on Friday after a steady run over the past month. Yet the real story sits in the income statement rather than the ticker. The latest half year numbers put a bright spotlight on profitability. Net profit margin now stands at 6% compared with 2.4% a year earlier and earnings over the past 12 months are sharply higher. That kind of margin rebuild matters more than a single day’s move. For long term investors in building ventilation and climate systems, the...
SWX:BUCN
SWX:BUCNMachinery

Bucher Industries (SWX:BUCN) Stock Looks Cheap But Margins Are Cracking

Bucher Industries stock closed at CHF316 after a choppy week that left shares down about 4.5% over seven days, even as the latest half year numbers landed. The market focused on softer profit metrics more than the headline revenue figure of CHF1,471.4m for H1 2026. Net income of CHF87.5m and basic earnings per share of CHF8.90 point to a profit squeeze that matters far more than a single day price move. For long term holders, the key question now is how this margin pressure fits with the...
SWX:UBSG
SWX:UBSGCapital Markets

UBS Group (SWX:UBSG) Stock Rides Profit Growth While Funding Risks Persist

UBS Group stock went into this earnings print with momentum, up about 24% over the past three months and trading at roughly 17x P/E, a premium to the wider European capital markets sector but below the Swiss market. Today the real story is not the headline share price move. It is whether investors trust a banking giant that is now posting quarterly net income of about US$2.8b while still carrying the memory of a US$5.0b one off hit in the recent past. The core tension for investors is simple...